Related Experiment Video
Updated: Aug 6, 2026

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
Published on: June 13, 2025
Intermittent Subcutaneous Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Pediatric Intensive Care
Autumn M Spyhalsky1, Kelli Jo Welter1, Mackenzie N DeVine1
1Department of Pharmacy, Children's Hospital Colorado, Aurora, Colorado, USA.
Subcutaneous unfractionated heparin (sUFH) for venous thromboembolism (VTE) prophylaxis in pediatric intensive care units (PICUs) showed bleeding in 24% and VTE in 11% of patients. Standardized dosing and further research are needed for sUFH safety and effectiveness in pediatric VTE prevention.
Area of Science:
- Pediatric critical care medicine
- Pharmacology and therapeutics
- Hematology and thrombosis
Background:
- Venous thromboembolism (VTE) is an increasing complication in pediatric intensive care units (PICUs).
- Intermittent subcutaneous unfractionated heparin (sUFH) is used for VTE prophylaxis in adults but lacks pediatric evidence.
- sUFH offers benefits in specific pediatric patient populations, including those with renal dysfunction or limited IV access.
Purpose of the Study:
- To characterize the prophylactic use of sUFH in a pediatric intensive care unit population.
- To evaluate the incidence of VTE and bleeding events associated with sUFH prophylaxis.
- To inform the development of standardized dosing strategies for pediatric VTE prophylaxis.
Main Methods:
- Retrospective cohort study of pediatric patients (≤ 18 years) receiving sUFH for VTE prophylaxis for ≥ 24 hours.
- Data collection included sUFH dosing, frequency, monitoring, and incidence of bleeding and VTE.
- Analysis compared outcomes between patients with and without VTE and bleeding events.
Main Results:
- Sixty-six pediatric patients received sUFH prophylaxis.
- The median sUFH dose was 89.3 units/kg, with dosing every 8 or 12 hours.
- VTE occurred in 11% of patients, and bleeding occurred in 24% of patients; no significant dose difference was observed between groups.
Conclusions:
- Bleeding events (24%) were more frequent than VTE events (11%) in pediatric patients receiving sUFH prophylaxis.
- Current sUFH dosing strategies may require standardization for improved safety and efficacy in the PICU.
- Further prospective studies are essential to establish optimal sUFH use for VTE prophylaxis in pediatric intensive care.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Drug Dosing: Infants and Children
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Continuous Renal Replacement Therapy
Pharmacokinetics in Pediatric Patients: Drug Distribution
